Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Biliverdin reductase and bilirubin in hepatic disease

Biliverdin reductase and bilirubin in hepatic disease The buildup of fat in the liver (hepatic steatosis) is the first step in a series of incidents that may drive hepatic disease. Obesity is the leading cause of nonalcoholic fatty liver disease (NAFLD), in which hepatic steatosis progresses to liver disease. Chronic alcohol exposure also induces fat accumulation in the liver and shares numerous similarities to obesity-induced NAFLD. Regardless of whether hepatic steatosis is due to obesity or long-term alcohol use, it still may lead to hepatic fibrosis, cirrhosis, or possibly hepatocellular carcinoma. The antioxidant bilirubin and the enzyme that generates it, biliverdin reductase A (BVRA), are components of the heme catabolic pathway that have been shown to reduce hepatic steatosis. This review discusses the roles for bilirubin and BVRA in the prevention of steatosis, their functions in the later stages of liver disease, and their potential therapeutic application. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AJP - Gastrointestinal and Liver Physiology The American Physiological Society

Biliverdin reductase and bilirubin in hepatic disease

Download PDF
9 pages

Loading next page...
1
 
/lp/aps/biliverdin-reductase-and-bilirubin-in-hepatic-disease-6sXc5GRB5g

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0193-1857
eISSN
1522-1547
DOI
10.1152/ajpgi.00026.2018
Publisher site
See Article on Publisher Site

Abstract

The buildup of fat in the liver (hepatic steatosis) is the first step in a series of incidents that may drive hepatic disease. Obesity is the leading cause of nonalcoholic fatty liver disease (NAFLD), in which hepatic steatosis progresses to liver disease. Chronic alcohol exposure also induces fat accumulation in the liver and shares numerous similarities to obesity-induced NAFLD. Regardless of whether hepatic steatosis is due to obesity or long-term alcohol use, it still may lead to hepatic fibrosis, cirrhosis, or possibly hepatocellular carcinoma. The antioxidant bilirubin and the enzyme that generates it, biliverdin reductase A (BVRA), are components of the heme catabolic pathway that have been shown to reduce hepatic steatosis. This review discusses the roles for bilirubin and BVRA in the prevention of steatosis, their functions in the later stages of liver disease, and their potential therapeutic application.

Journal

AJP - Gastrointestinal and Liver Physiology – The American Physiological Society

Published: Jun 1, 2018

References

  • Bilirubin as a potential causal factor in type 2 diabetes risk: a Mendelian randomization study
    Abbasi, A; Deetman, PE; Corpeleijn, E; Gansevoort, RT; Gans, RO; Hillege, HL; van der Harst, P; Stolk, RP; Navis, G; Alizadeh, BZ; Bakker, SJ
  • Human biliverdin reductase is a leucine zipper-like DNA-binding protein and functions in transcriptional activation of heme oxygenase-1 by oxidative stress
    Ahmad, Z; Salim, M; Maines, MD
  • Biliverdin reductase: a major physiologic cytoprotectant
    Baranano, DE; Rao, M; Ferris, CD; Snyder, SH
  • Liver fibrosis
    Bataller, R; Brenner, DA
  • Body fat percentage is a major determinant of total bilirubin independently of UGT1A1*28 polymorphism in young obese
    Belo, L; Nascimento, H; Kohlova, M; Bronze-da-Rocha, E; Fernandes, J; Costa, E; Catarino, C; Aires, L; Mansilha, HF; Rocha-Pereira, P; Quintanilha, A; Rêgo, C; Santos-Silva, A
  • Comparative redox status in alcoholic liver disease and nonalcoholic fatty liver disease
    Bhardwaj, P; Madan, K; Thareja, S; Joshi, YK; Saraya, A
  • Changes in bilirubins in human prenatal development
    Blumenthal, SG; Stucker, T; Rasmussen, RD; Ikeda, RM; Ruebner, BH; Bergstrom, DE; Hanson, FW
  • Alcoholic liver disease
    Bruha, R; Dvorak, K; Petrtyl, J
  • Modulation of PPAR activity via phosphorylation
    Burns, KA; Vanden Heuvel, JP
  • Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21
    Camporez, JP; Asrih, M; Zhang, D; Kahn, M; Samuel, VT; Jurczak, MJ; Jornayvaz, FR
  • Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review
    Cazzo, E; Pareja, JC; Chaim, EA
  • Pathogenesis of alcoholic liver disease: role of oxidative metabolism
    Ceni, E; Mello, T; Galli, A
  • Inverse relationship between serum bilirubin levels and diabetic foot in Chinese patients with type 2 diabetes mellitus
    Chen, J; Wang, J; Zhang, X; Zhu, H
  • Absence of the biliverdin reductase-a gene is associated with increased endogenous oxidative stress
    Chen, W; Maghzal, GJ; Ayer, A; Suarna, C; Dunn, LL; Stocker, R
  • Alcoholic fatty liver is enhanced in CYP2A5 knockout mice: the role of the PPARα-FGF21 axis
    Chen, X; Ward, SC; Cederbaum, AI; Xiong, H; Lu, Y
  • Initial-rate kinetics of the flavin reductase reaction catalysed by human biliverdin-IXβ reductase (BVR-B)
    Cunningham, O; Gore, MG; Mantle, TJ
  • Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide
    D’Andrea, V; Pérez, LM; Sánchez Pozzi, EJ
  • FGF21 mediates the lipid metabolism response to amino acid starvation
    De Sousa-Coelho, AL; Relat, J; Hondares, E; Pérez-Martí, A; Ribas, F; Villarroya, F; Marrero, PF; Haro, D
  • The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus
    Dekker, D; Dorresteijn, MJ; Pijnenburg, M; Heemskerk, S; Rasing-Hoogveld, A; Burger, DM; Wagener, FA; Smits, P
  • α-SMA overexpression associated with increased liver fibrosis in infants with biliary atresia
    Dong, R; Luo, Y; Zheng, S
  • Pathogenesis of non-alcoholic fatty liver disease
    Dowman, JK; Tomlinson, JW; Newsome, PN
  • Bilirubin-induced immunostimulant effects and toxicity vary with neural cell type and maturation state
    Falcão, AS; Fernandes, A; Brito, MA; Silva, RF; Brites, D
  • Plasma bilirubin pigments in health and disease
    Fevery, J; Muraca, M; Mesa, V; Van Steenbergen, W; Blanckaert, N
  • Bile pigment metabolism
    Fevery, J; Vanstapel, F; Blanckaert, N
  • Gilbert syndrome
    Fretzayas, A; Moustaki, M; Liapi, O; Karpathios, T
  • Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver
    Friedman, SL
  • The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice
    Fritz, WA; Lin, TM; Safe, S; Moore, RW; Peterson, RE
  • Human biliverdin reductase-based peptides activate and inhibit glucose uptake through direct interaction with the kinase domain of insulin receptor
    Gibbs, PE; Lerner-Marmarosh, N; Poulin, A; Farah, E; Maines, MD
  • Nanoparticle delivered human biliverdin reductase-based peptide increases glucose uptake by activating IRK/Akt/GSK3 axis: the peptide is effective in the cell and wild-type and diabetic Ob/Ob mice
    Gibbs, PE; Miralem, T; Lerner-Marmarosh, N; Maines, MD
  • Biliverdin reductase: a target for cancer therapy?
    Gibbs, PE; Miralem, T; Maines, MD
  • Protective role of biliverdin against bile acid-induced oxidative stress in liver cells
    Gonzalez-Sanchez, E; Perez, MJ; Nytofte, NS; Briz, O; Monte, MJ; Lozano, E; Serrano, MA; Marin, JJG
  • Unconjugated bilirubin activates and damages microglia
    Gordo, AC; Falcão, AS; Fernandes, A; Brito, MA; Silva, RF; Brites, D
  • Inverse association of serum bilirubin with metabolic syndrome and insulin resistance in Polish population
    Guzek, M; Jakubowski, Z; Bandosz, P; Wyrzykowski, B; Smoczyński, M; Jabloiska, A; Zdrojewski, T
  • Bilirubin in the liver-gut signaling axis
    Hamoud, AR; Weaver, L; Stec, DE; Hinds, TD
  • Higher bilirubin levels of healthy living liver donors are associated with lower posttransplant hepatocellular carcinoma recurrence
    Han, S; Yang, JD; Sinn, DH; Ko, JS; Kim, JM; Shin, JC; Son, HJ; Gwak, MS; Joh, JW; Kim, GS
  • Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic
    Hassan, K; Bhalla, V; El Regal, ME; A-Kader, HH
  • Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK) 3β phosphorylation of serine 73 of peroxisome proliferator-activated receptor (PPAR) α
    Hinds, TD; Burns, KA; Hosick, PA; McBeth, L; Nestor-Kalinoski, A; Drummond, HA; AlAmodi, AA; Hankins, MW; Vanden Heuvel, JP; Stec, DE
  • Mice with hyperbilirubinemia due to Gilbert’s syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα
    Hinds, TD; Hosick, PA; Chen, S; Tukey, RH; Hankins, MW; Nestor-Kalinoski, A; Stec, DE
  • Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21
    Hinds, TD; Sodhi, K; Meadows, C; Fedorova, L; Puri, N; Kim, DH; Peterson, SJ; Shapiro, J; Abraham, NG; Kappas, A
  • Alpha-smooth muscle actin expression upregulates fibroblast contractile activity
    Hinz, B; Celetta, G; Tomasek, JJ; Gabbiani, G; Chaponnier, C
  • Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH)
    Hjelkrem, M; Morales, A; Williams, CD; Harrison, SA
  • Hepatic FGF21 expression is induced at birth via PPARα in response to milk intake and contributes to thermogenic activation of neonatal brown fat
    Hondares, E; Rosell, M; Gonzalez, FJ; Giralt, M; Iglesias, R; Villarroya, F
  • Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease
    Hopkins, PN; Wu, LL; Hunt, SC; James, BC; Vincent, GM; Williams, RR
  • Biliverdin reductase A (BVRA) mediates macrophage expression of interleukin-10 in injured kidney
    Hu, Z; Pei, G; Wang, P; Yang, J; Zhu, F; Guo, Y; Wang, M; Yao, Y; Zeng, R; Liao, W; Xu, G
  • Reactive oxygen species in the normal and acutely injured liver
    Jaeschke, H; Ramachandran, A
  • Elevated serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
    Jang, BK
  • Direct antioxidant properties of bilirubin and biliverdin. Is there a role for biliverdin reductase?
    Jansen, T; Daiber, A
  • Serum bilirubin levels are lower in overweight asymptomatic middle-aged adults: an early indicator of metabolic syndrome?
    Jenko-Pražnikar, Z; Petelin, A; Jurdana, M; Žiberna, L
  • Elevated serum bilirubin levels are inversely associated with coronary artery atherosclerosis
    Kang, SJ; Kim, D; Park, HE; Chung, GE; Choi, SH; Choi, SY; Lee, W; Kim, JS; Cho, SH
  • Relationship between serum bilirubin levels and metabolic syndrome in patients with schizophrenia spectrum disorders
    Karadag, F; Sengul, CB; Enli, Y; Karakulah, K; Alacam, H; Kaptanoglu, B; Kalkanci, O; Herken, H
  • Tat-biliverdin reductase A inhibits inflammatory response by regulation of MAPK and NF-κB pathways in Raw 264.7 cells and edema mouse model
    Kim, HR; Kim, DW; Jo, HS; Cho, SB; Park, JH; Lee, CH; Choi, YJ; Yeo, EJ; Park, SY; Kim, ST; Yu, YH; Kim, DS; Kim, HA; Cho, SW; Han, KH; Park, J; Eum, WS; Choi, SY
  • Bilirubin nanoparticle preconditioning protects against hepatic ischemia-reperfusion injury
    Kim, JY; Lee, DY; Kang, S; Miao, W; Kim, H; Lee, Y; Jon, S
  • Unconjugated hyperbilirubinemia in patients with non-alcoholic fatty liver disease: a favorable endogenous response
    Kumar, R; Rastogi, A; Maras, JS; Sarin, SK
  • Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
    Kwak, MS; Kim, D; Chung, GE; Kang, SJ; Park, MJ; Kim, YJ; Yoon, JH; Lee, HS
  • Inverse association between total bilirubin and metabolic syndrome in rural Korean women
    Kwon, KM; Kam, JH; Kim, MY; Kim, MY; Chung, CH; Kim, JK; Linton, JA; Eom, A; Koh, SB; Kang, HT
  • Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States
    Le, MH; Devaki, P; Ha, NB; Jun, DW; Te, HS; Cheung, RC; Nguyen, MH
  • Tat-biliverdin reductase A protects INS-1 cells from human islet amyloid polypeptide-induced cytotoxicity by alleviating oxidative stress and ER stress
    Lee, SJ; Kang, HK; Eum, WS; Park, J; Choi, SY; Kwon, HY
  • Bilirubin nanoparticles as a nanomedicine for anti-inflammation therapy
    Lee, Y; Kim, H; Kang, S; Lee, J; Park, J; Jon, S
  • The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
    Li, L; Zhao, GD; Shi, Z; Qi, LL; Zhou, LY; Fu, ZX
  • Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study
    Lin, JP; O’Donnell, CJ; Schwaiger, JP; Cupples, LA; Lingenhel, A; Hunt, SC; Yang, S; Kronenberg, F
  • Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease
    Lin, YC; Chang, PF; Hu, FC; Chang, MH; Ni, YH
  • Unconjugated bilirubin contributes to early inflammation and edema after intracerebral hemorrhage
    Loftspring, MC; Johnson, HL; Feng, R; Johnson, AJ; Clark, JF
  • The prevalence of nonalcoholic fatty liver disease in the Americas
    López-Velázquez, JA; Silva-Vidal, KV; Ponciano-Rodríguez, G; Chávez-Tapia, NC; Arrese, M; Uribe, M; Méndez-Sánchez, N
  • Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase
    Maghzal, GJ; Leck, MC; Collinson, E; Li, C; Stocker, R
  • Biliverdin reductase: PKC interaction at the cross-talk of MAPK and PI3K signaling pathways
    Maines, MD
  • Glucocorticoid receptor β induces hepatic steatosis by augmenting inflammation and inhibition of the peroxisome proliferator-activated receptor (PPAR) α
    Marino, JS; Stechschulte, LA; Stec, DE; Nestor-Kalinoski, A; Coleman, S; Hinds, TD
  • Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease
    Matsuda, S; Kobayashi, M; Kitagishi, Y
  • Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations
    Milić, S; Lulić, D; Štimac, D
  • Interaction of human biliverdin reductase with Akt/protein kinase B and phosphatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: a novel mechanism of Akt activation
    Miralem, T; Lerner-Marmarosh, N; Gibbs, PE; Jenkins, JL; Heimiller, C; Maines, MD
  • The human biliverdin reductase-based peptide fragments and biliverdin regulate protein kinase Cδ activity: the peptides are inhibitors or substrate for the protein kinase C
    Miralem, T; Lerner-Marmarosh, N; Gibbs, PE; Tudor, C; Hagen, FK; Maines, MD
  • Obesity, visceral fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease
    Mirza, MS
  • Obesity: overview of an epidemic
    Mitchell, NS; Catenacci, VA; Wyatt, HR; Hill, JO
  • Features of an altered AMPK metabolic pathway in Gilbert’s syndrome, and its role in metabolic health
    Mölzer, C; Wallner, M; Kern, C; Tosevska, A; Schwarz, U; Zadnikar, R; Doberer, D; Marculescu, R; Wagner, KH
  • Management of alcoholic hepatitis
    Morgan, TR
  • Obesity and fatty liver are prevented by inhibition of the aryl hydrocarbon receptor in both female and male mice
    Moyer, BJ; Rojas, IY; Kerley-Hamilton, JS; Nemani, KV; Trask, HW; Ringelberg, CS; Gimi, B; Demidenko, E; Tomlinson, CR
  • Biliverdin reductase isozymes in metabolism
    O’Brien, L; Hosick, PA; John, K; Stec, DE; Hinds, TD
  • Studies in kernicterus. I. The protein binding of bilirubin
    Odell, GB
  • Bilirubin inhibits tumor cell growth via activation of ERK
    Ollinger, R; Kogler, P; Troppmair, J; Hermann, M; Wurm, M; Drasche, A; Königsrainer, I; Amberger, A; Weiss, H; Ofner, D; Bach, FH; Margreiter, R
  • Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes
    Oreña, SJ; Torchia, AJ; Garofalo, RS
  • Recognition of lipopolysaccharide pattern by TLR4 complexes
    Park, BS; Lee, JO
  • Non alcoholic fatty liver disease and metabolic syndrome
    Paschos, P; Paletas, K
  • Structure of human biliverdin IXβ reductase, an early fetal bilirubin IXβ producing enzyme
    Pereira, PJ; Macedo-Ribeiro, S; Párraga, A; Pérez-Luque, R; Cunningham, O; Darcy, K; Mantle, TJ; Coll, M
  • Serum bilirubin level is inversely associated with nonalcoholic steatohepatitis in children
    Puri, K; Nobili, V; Melville, K; Corte, CD; Sartorelli, MR; Lopez, R; Feldstein, AE; Alkhouri, N
  • Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis
    Reeves, HL; Burt, AD; Wood, S; Day, CP
  • Jaundice in the adult patient
    Roche, SP; Kobos, R
  • Redox functions of heme oxygenase-1 and biliverdin reductase in diabetes
    Rochette, L; Zeller, M; Cottin, Y; Vergely, C
  • Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis
    Salomone, F; Li Volti, G; Rosso, C; Grosso, G; Bugianesi, E
  • A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis
    Schlezinger, JJ; Liu, D; Farago, M; Seldin, DC; Belguise, K; Sonenshein, GE; Sherr, DH
  • Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin
    Schwertner, HA; Vítek, L
  • Bilirubin and glutathione have complementary antioxidant and cytoprotective roles
    Sedlak, TW; Saleh, M; Higginson, DS; Paul, BD; Juluri, KR; Snyder, SH
  • Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle
    Sedlak, TW; Snyder, SH
  • Depletion of stercobilin in fecal matter from a mouse model of autism spectrum disorders
    Sekera, ER; Rudolph, HL; Carro, SD; Morales, MJ; Bett, GCL; Rasmusson, RL; Wood, TD
  • TLR4 enhances TGF-β signaling and hepatic fibrosis
    Seki, E; De Minicis, S; Osterreicher, CH; Kluwe, J; Osawa, Y; Brenner, DA; Schwabe, RF
  • Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites
    Sérée, E; Villard, PH; Pascussi, JM; Pineau, T; Maurel, P; Nguyen, QB; Fallone, F; Martin, PM; Champion, S; Lacarelle, B; Savouret, JF; Barra, Y
  • Aryl hydrocarbon receptor-dependent induction of Cyp1a1 by bilirubin in mouse hepatoma Hepa 1c1c7 cells
    Sinal, CJ; Bend, JR
  • Microbiota-dependent hepatic lipogenesis mediated by stearoyl CoA desaturase 1 (SCD1) promotes metabolic syndrome in TLR5-deficient mice
    Singh, V; Chassaing, B; Zhang, L; San Yeoh, B; Xiao, X; Kumar, M; Baker, MT; Cai, J; Walker, R; Borkowski, K; Harvatine, KJ; Singh, N; Shearer, GC; Ntambi, JM; Joe, B; Patterson, AD; Gewirtz, AT; Vijay-Kumar, M
  • Effect of low serum total bilirubin levels (≤0.32 mg/dl) on risk of coronary artery disease in patients with metabolic syndrome
    Song, YS; Koo, BK; Cho, NH; Moon, MK
  • Mitogen inactivation of glycogen synthase kinase-3β in intact cells via serine 9 phosphorylation
    Stambolic, V; Woodgett, JR
  • Bilirubin binding to PPARα inhibits lipid accumulation
    Stec, DE; John, K; Trabbic, CJ; Luniwal, A; Hankins, MW; Baum, J; Hinds, TD
  • Glucocorticoid receptor β stimulates Akt1 growth pathway by attenuation of PTEN
    Stechschulte, LA; Wuescher, L; Marino, JS; Hill, JW; Eng, C; Hinds, TD
  • Inhibitory effect of the low-toxic exogenous aryl hydrocarbon receptor modulator 3′3-diindolylmethane on gastric cancer in mice
    Su, M; Qian, C; Hu, Y; Lu, W; Huang, R; Chen, M; Chen, J
  • Glucuronidation and UGT isozymes in bladder: new targets for the treatment of uroepithelial carcinomas?
    Sundararaghavan, VL; Sindhwani, P; Hinds, TD
  • Low concentrations of bilirubin inhibit activation of hepatic stellate cells in vitro
    Tang, Y; Zhang, Q; Zhu, Y; Chen, G; Yu, F
  • Bilirubin: its role in cytoprotection against oxidative stress
    Tomaro, ML; Batlle, AM
  • Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease
    Toshikuni, N; Tsutsumi, M; Arisawa, T
  • Peroxisome proliferator-activated receptor (PPAR)-α: a pharmacological target with a promising future
    van Raalte, DH; Li, M; Pritchard, PH; Wasan, KM
  • PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation
    Varga, T; Czimmerer, Z; Nagy, L
  • Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice
    Vera, T; Granger, JP; Stec, DE
  • The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases
    Vítek, L
  • Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels
    Vítek, L; Jirsa, M; Brodanová, M; Kalab, M; Marecek, Z; Danzig, V; Novotný, L; Kotal, P
  • Bilirubin prevents atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice by inhibiting endothelial VCAM-1 and ICAM-1 signaling
    Vogel, ME; Idelman, G; Konaniah, ES; Zucker, SD
  • Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert’s syndrome
    Wallner, M; Marculescu, R; Doberer, D; Wolzt, M; Wagner, O; Vitek, L; Bulmer, AC; Wagner, KH
  • Bilirubin can induce tolerance to islet allografts
    Wang, H; Lee, SS; Dell’Agnello, C; Tchipashvili, V; d’Avila, JC; Czismadia, E; Chin, BY; Bach, FH
  • Bilirubin metabolism: applied physiology
    Wang, XC; Chowdhury, JR; Chowdhury, NR
  • Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver
    Washington, K; Wright, K; Shyr, Y; Hunter, EB; Olson, S; Raiford, DS
  • Cell surface biliverdin reductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt
    Wegiel, B; Baty, CJ; Gallo, D; Csizmadia, E; Scott, JR; Akhavan, A; Chin, BY; Kaczmarek, E; Alam, J; Bach, FH; Zuckerbraun, BS; Otterbein, LE
  • Biliverdin inhibits Toll-like receptor-4 (TLR4) expression through nitric oxide-dependent nuclear translocation of biliverdin reductase
    Wegiel, B; Gallo, D; Csizmadia, E; Roger, T; Kaczmarek, E; Harris, C; Zuckerbraun, BS; Otterbein, LE
  • Heme oxygenase: a novel target for the modulation of the inflammatory response
    Willis, D; Moore, AR; Frederick, R; Willoughby, DA
  • A selective aryl hydrocarbon receptor modulator 3,3′-diindolylmethane inhibits gastric cancer cell growth
    Yin, XF; Chen, J; Mao, W; Wang, YH; Chen, MH
  • Unconjugated bilirubin ameliorates the inflammation and digestive protease increase in TNBS-induced colitis
    Zhou, JA; Jiang, M; Yang, X; Liu, Y; Guo, J; Zheng, J; Qu, Y; Song, Y; Li, R; Qin, X; Wang, X
  • Relationship between the serum total bilirubin and inflammation in patients with psoriasis vulgaris
    Zhou, ZX; Chen, JK; Hong, YY; Zhou, R; Zhou, DM; Sun, LY; Qin, WL; Wang, TC
  • Effect of bilirubin concentration on the risk of diabetic complications: a meta-analysis of epidemiologic studies
    Zhu, B; Wu, X; Bi, Y; Yang, Y
  • Bilirubin protects grafts against nonspecific inflammation-induced injury in syngeneic intraportal islet transplantation
    Zhu, H; Wang, J; Jiang, H; Ma, Y; Pan, S; Reddy, S; Sun, X
  • Bilirubin is an endogenous antioxidant in human vascular endothelial cells
    Ziberna, L; Martelanc, M; Franko, M; Passamonti, S